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Abstract—A cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus, which occur together more
often than by chance alone, have become known as the metabolic syndrome. The risk factors include raised blood
pressure, dyslipidemia (raised triglycerides and lowered high-density lipoprotein cholesterol), raised fasting
glucose, and central obesity. Various diagnostic criteria have been proposed by different organizations over the
past decade. Most recently, these have come from the International Diabetes Federation and the American Heart
Association/National Heart, Lung, and Blood Institute. The main difference concerns the measure for central
obesity, with this being an obligatory component in the International Diabetes Federation definition, lower than in
the American Heart Association/National Heart, Lung, and Blood Institute criteria, and ethnic specific. The present
article represents the outcome of a meeting between several major organizations in an attempt to unify criteria. It
was agreed that there should not be an obligatory component, but that waist measurement would continue to be
a useful preliminary screening tool. Three abnormal findings out of 5 would qualify a person for the metabolic
syndrome. A single set of cut points would be used for all components except waist circumference, for which
further work is required. In the interim, national or regional cut points for waist circumference can be used.
(Circulation. 2009;120:1640-1645.)
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The metabolic syndrome is a complex of interrelated riskfactors for cardiovascular disease (CVD) and diabetes.
These factors include dysglycemia, raised blood pressure,
elevated triglyceride levels, low high-density lipoprotein
cholesterol levels, and obesity (particularly central adiposity).
The associations and clustering of these factors have been
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known for decades. Recent interest has focused on the
possible involvement of insulin resistance as a linking factor,
although the pathogenesis remains unclear, as does the
establishment of diagnostic criteria. With these risk factors, it
has been demonstrated clearly that the syndrome is common
and that it has a rising prevalence worldwide, which relates
largely to increasing obesity and sedentary lifestyles. As a
result, the metabolic syndrome is now both a public health
and a clinical problem. In the public health arena, more
attention must be given to modification of lifestyles of the
general public of all nations to reduce obesity and to increase
physical activity. At a clinical level, individual patients with
the metabolic syndrome need to be identified so that their
multiple risk factors, including lifestyle risk factors, can be
reduced.
Although there is general agreement in the medical
community that obesity and its medical complications,
including the metabolic syndrome, deserve greater atten-
tion, there has been considerable disagreement over the
terminology and diagnostic criteria related to the metabolic
syndrome. Despite this disagreement, there appears to be a
consensus in the medical field that the term metabolic
syndrome is acceptable for the condition of the presence of
multiple metabolic risk factors for CVD and diabetes. On
the other hand, several clinical definitions of the metabolic
syndrome have been proposed. This has led to some
confusion on the part of clinicians regarding how to
identify patients with the syndrome. Some controversy
also exists about whether the metabolic syndrome is a true
syndrome or a mixture of unrelated phenotypes. A syn-
drome is simply a clustering of factors that occur together
more often than by chance alone and for which the cause
is often uncertain. The metabolic syndrome fulfills these
criteria. The metabolic syndrome is not an absolute risk
indicator, because it does not contain many of the factors
that determine absolute risk, for example, age, sex, ciga-
rette smoking, and low-density lipoprotein cholesterol
levels. Nonetheless, patients with the metabolic syndrome
are at twice the risk of developing CVD over the next 5 to
10 years as individuals without the syndrome. The risk
over a lifetime undoubtedly is even higher. Furthermore,
the metabolic syndrome confers a 5-fold increase in risk
for type 2 diabetes mellitus. The most widely recognized
of the metabolic risk factors are atherogenic dyslipidemia,
elevated blood pressure, and elevated plasma glucose. In
addition, persons with these characteristics commonly
manifest a prothrombotic state and a proinflammatory
state. Atherogenic dyslipidemia consists of an aggregation
of lipoprotein abnormalities that includes elevated serum
triglyceride and apolipoprotein B, increased small low-
density lipoprotein particles, and a reduced level of high-
density lipoprotein cholesterol. Most persons with the
metabolic syndrome have abdominal obesity and insulin
resistance. Both of the latter conditions appear to contrib-
ute to the development of metabolic risk factors, although
the mechanisms underlying these contributions are not
fully understood.
The first formalized definition of the metabolic syndrome
was proposed in 1998 by a consultation group on the
definition of diabetes for the World Health Organization
(WHO).1 This group emphasized insulin resistance as the
major underlying risk factor and required evidence of insulin
resistance for diagnosis. A diagnosis of the syndrome by
WHO criteria could thus be made on the basis of several
markers of insulin resistance plus 2 additional risk factors,
including obesity, hypertension, high triglyceride level, re-
duced high-density lipoprotein cholesterol level, or microal-
buminuria. Patients with type 2 diabetes mellitus were not
excluded from diagnosis. The other major criteria came from
the National Cholesterol Education Program Adult Treatment
Panel III (ATP III)2 in 2001. ATP III criteria did not require
demonstration of insulin resistance per se. Moreover, no
single factor was required for diagnosis, but instead, ATP III
made the presence of 3 of the following 5 factors the basis for
establishing the diagnosis: Abdominal obesity (which is
highly correlated with insulin resistance), elevated triglycer-
ide, reduced high-density lipoprotein cholesterol, elevated
blood pressure, and elevated fasting glucose (impaired fasting
glucose or type 2 diabetes mellitus). In the absence of CVD
or diabetes, the metabolic syndrome is a predictor of these
conditions. Once CVD or diabetes develops, the metabolic
syndrome is often present, and the number of components of
the metabolic syndrome contributes to disease progression
and risk.
In 2005, both the International Diabetes Federation (IDF)3
and the American Heart Association/National Heart, Lung,
and Blood Institute (AHA/NHLBI)4 attempted to reconcile
the different clinical definitions. In spite of this effort, their
separate recommendations contained differences related to
waist circumference. The IDF dropped the WHO requirement
for insulin resistance but made abdominal obesity necessary
as 1 of 5 factors required in the diagnosis, with particular
emphasis on waist measurement as a simple screening tool;
the remainder of the criteria were essentially identical to
those provided by ATP III. The AHA/NHLBI slightly mod-
ified the ATP III criteria but did not mandate abdominal
obesity as a required risk factor. The remaining 4 risk factors
were identical in definition to those of the IDF. Moreover,
there was no agreement on the definition of abdominal
obesity between the IDF and AHA/NHLBI. The IDF recom-
mended that the threshold for waist circumference to define
abdominal obesity in people of European origin (Europids)
should be 94 cm for men and 80 cm for women; the
AHA/NHLBI, in contrast, recommended cut points of 102
and 88 cm, respectively, for the 2 sexes. The latter values
are consistent with the definitions of abdominal obesity found
in National Institutes of Health obesity guidelines,5 which
equate to a body mass index of approximately 30 kg/m2 in
males. The IDF values are closer to a body mass index of 25
kg/m2 in males. The IDF guidelines also stressed the need to
adopt different values for waist measurement in different
ethnic groups based on the relationship of waist measurement
either to the other metabolic syndrome components or to
longer-term outcome studies such as those on the risk of type
2 diabetes mellitus and CVD.
Recently, IDF and AHA/NHLBI representatives held dis-
cussions to attempt to resolve the remaining differences
between definitions of metabolic syndrome. Both sides
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agreed that abdominal obesity should not be a prerequisite for
diagnosis but that it is 1 of 5 criteria, so that the presence of
any 3 of 5 risk factors constitutes a diagnosis of metabolic
syndrome. This would result in the common definition shown
in Table 1.
Defining thresholds for abdominal obesity is compli-
cated, in part because of differences in the relation of
abdominal obesity to other metabolic risk factors. In
addition, predictive values for various levels of abdominal
obesity for CVD and diabetes may differ. There is also the
problem of generating cut points for continuous variables,
although this is true for all components of the syndrome.
However, what is particularly needed is evidence based on
both cross-sectional and longitudinal data relating waist
circumference to risk for both CVD and type 2 diabetes. It
is clear that there are and will continue to be differences
between sexes and ethnic groups. In addition, there is the
practical consideration of what threshold justifies the
expenditure of national medical resources for clinical
intervention (eg, nutritional and physical activity counsel-
ing) in contrast to public health intervention. Of course,
this does not mean that there should not be agreed-upon
international criteria based on evidence but rather that a
particular health system might adopt different cutoff points
locally for pragmatic or economic reasons. Long-term
prospective studies are required to reach more reliable
waist circumference cut points for different ethnic groups,
particularly for women.
Neither ATP III nor IDF criteria excluded hyperglycemia
in the diabetes range as 1 of the 5 criteria for diagnosis of the
metabolic syndrome. By these criteria, most patients with
type 2 diabetes mellitus have the metabolic syndrome. More-
over, those with type 2 diabetes mellitus are at higher
long-term risk for developing CVD. The same is true for
patients with type 1 diabetes mellitus. Therefore, any patient
with diabetes mellitus who has other metabolic risk factors
should be treated with lifestyle intervention, followed by
drugs if necessary, to favorably modify other components of
the syndrome.
Table 2 shows current international recommendations
proposed by the IDF for thresholds of abdominal obesity to
be used as 1 component of the metabolic syndrome.3 Table
2 also lists waist circumference thresholds currently being
recommended in several different populations and ethnic
Table 1. Criteria for Clinical Diagnosis of the
Metabolic Syndrome
Measure Categorical Cut Points
Elevated waist circumference* Population- and
country-specific definitions
Elevated triglycerides (drug treatment
for elevated triglycerides is an
alternate indicator†)
150 mg/dL (1.7 mmol/L)
Reduced HDL-C (drug treatment for
reduced HDL-C is an alternate
indicator†)
40 mg/dL (1.0 mmol/L) in
males;
50 mg/dL (1.3 mmol/L) in
females
Elevated blood pressure
(antihypertensive drug treatment in a
patient with a history of hypertension
is an alternate indicator)
Systolic 130 and/or diastolic
85 mm Hg
Elevated fasting glucose‡ (drug
treatment of elevated glucose is an
alternate indicator)
100 mg/dL
HDL-C indicates high-density lipoprotein cholesterol.
*It is recommended that the IDF cut points be used for non-Europeans and
either the IDF or AHA/NHLBI cut points used for people of European origin until
more data are available.
†The most commonly used drugs for elevated triglycerides and reduced
HDL-C are fibrates and nicotinic acid. A patient taking 1 of these drugs can be
presumed to have high triglycerides and low HDL-C. High-dose -3 fatty acids
presumes high triglycerides.
‡Most patients with type 2 diabetes mellitus will have the metabolic
syndrome by the proposed criteria.
Table 2. Current Recommended Waist Circumference Thresholds for Abdominal Obesity by Organization
Recommended Waist Circumference Threshold for
Abdominal Obesity
Population Organization (Reference) Men Women
Europid IDF (4) 94 cm 80 cm
Caucasian WHO (7) 94 cm (increased risk) 80 cm (increased risk)
102 cm (still higher risk) 88 cm (still higher risk)
United States AHA/NHLBI (ATP III)* (5) 102 cm 88 cm
Canada Health Canada (8,9) 102 cm 88 cm
European European Cardiovascular Societies (10) 102 cm 88 cm
Asian (including Japanese) IDF (4) 90 cm 80 cm
Asian WHO (11) 90 cm 80 cm
Japanese Japanese Obesity Society (12) 85 cm 90 cm
China Cooperative Task Force (13) 85 cm 80 cm
Middle East, Mediterranean IDF (4) 94 cm 80 cm
Sub-Saharan African IDF (4) 94 cm 80 cm
Ethnic Central and South American IDF (4) 90 cm 80 cm
*Recent AHA/NHLBI guidelines for metabolic syndrome recognize an increased risk for CVD and diabetes at waist-circumference thresholds of 94 cm in men
and 80 cm in women and identify these as optional cut points for individuals or populations with increased insulin resistance.
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groups. One key question is whether the same criteria
should be applied to someone of a particular ethnic group
regardless of their country of residence. This would be
logical. IDF waist circumference recommendations for the
metabolic syndrome are the same for women everywhere
owing in part to the paucity of good data, but they are
somewhat higher for men of European origin (Europids)
than for those of Asian origin. Levels for Asian popula-
tions are based on WHO recommendations.6 Fewer data
are available for other regions, but Europid male recom-
mendations are applied to men of the Middle East, Eastern
Mediterranean region, and Sub-Saharan Africa pending the
provision of new data.
WHO7 identifies 2 levels of abdominal obesity in Europids
depending on risk for metabolic complications. An increased
risk occurs at waist circumferences of 94 cm in men and
80 cm in women, but risk is substantially higher at 102
cm in men and 88 cm in women. Higher thresholds
generally are used to define abdominal obesity in the United
States,7 Canada,8,9 and Europe.10 These higher thresholds also
are used as the waist circumference cut points to identify the
metabolic syndrome in the United States. Compared with
Europids, an expert consultation for WHO indicated that cut
points in the Asian population should be90 cm for men and
80 cm for women.6 Several different levels have been
suggested in Japan,11,12 with cutoff points of 85 to 90 cm
for men and 80 cm for women suggested by the newest
studies in contrast with the original cutoff points.13 In China,
cutoff points of 85 cm in men and 80 cm in women have
been suggested,14 and slightly lower values have been sug-
gested in India.
If the higher waist circumference cut points are used to
diagnose the metabolic syndrome, fewer individuals
should be identified as having the syndrome than if the
lower cut point is used. This is true for some countries of
the world.15 However, when the NHLBI/AHA definition is
used for the United States with the higher or lower cut
points, the difference in metabolic syndrome prevalence is
relatively small, both because abdominal obesity is highly
correlated with the other 4 components of the syndrome16
and because the prevalence of obesity is so high (Figure).
We now propose common criteria for the clinical diag-
nosis of the metabolic syndrome based on the criteria
shown in Table 1. This definition recognizes that the risk
associated with a particular waist measurement will differ
in different populations. Whether it is better at this time to
set the level at which risk starts to increase or at which
there is already substantially increased risk will be up to
local decision-making groups. However, for international
comparisons and to facilitate the etiology, it is critical that
a commonly agreed-upon set of criteria be used worldwide,
with agreed-upon cut points for different ethnic groups and
sexes. Obviously, there are many people in the world of
mixed ethnicity, and in these cases, pragmatic decisions
will have to be made.
It is expected that new expert groups will be formed to
assess the evidence with regard to waist circumference
thresholds and associated risk in the near future. These
include WHO and NHLBI. Both organizational bodies are
reconsidering the definition of metabolic syndrome, and we
hope that the present scientific statement will provide a useful
platform for their discussions. We believe that current rec-
ommended waist thresholds should be used pro tempore,
although it would be helpful if both the lower and higher
criteria for Europids were cited for comparative studies.
Some new data are available for different ethnic groups, but
it is thought advisable to await the outcomes of the deliber-
ations of WHO and NHLBI, when our group will reconvene
to produce a further statement with the intention of having a
single agreed-upon set of diagnostic criteria. We would stress
that the process is evolutionary. In the interim, further studies
exploring the relation of waist circumference thresholds to
metabolic risk and cardiovascular outcomes in different
populations are encouraged, and we continue to recommend
the use of waist measurement as a useful screening tool in
many primary care situations.
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